by Leanne Talbot | Apr 21, 2021
21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults... 
